Product image of Jidinum (Sitagliptin) supplied by GNH India

Jidinum

Active Ingredient:
Sitagliptin
Origin:
EU

Jidinum (Sitagliptin)

Sitagliptin, the active ingredient in Jidinum, is a dipeptidyl‑peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is used to improve glycaemic control in adult patients with type 2 diabetes mellitus, often in combination with diet and exercise.

GNH India supplies Jidinum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines. The company adheres to stringent regulatory standards and ensures consistent product availability across global markets. Our distribution network includes major healthcare institutions and specialty pharmacies.

Manufacturer / TM Owner

Medochemie Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels as monotherapy.
  • Combination with metformin: enhances overall glycaemic control when metformin alone is insufficient.
  • Adjunct to insulin: reduces required insulin dose and mitigates hypoglycaemia risk.
  • Use with diet and exercise: supports blood sugar management alongside lifestyle modifications.
  • Combination with sulfonylureas: provides additional glucose‑lowering effect, but requires monitoring for hypoglycaemia.

How It Works

  • Sitagliptin selectively inhibits the enzyme dipeptidyl‑peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By blocking DPP‑4, endogenous incretin levels rise, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby improving post‑prandial and overall glycaemic control.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nose and throat.
  • Headache: transient cranial discomfort.
  • Upper respiratory tract infection: symptoms of cough and congestion.
  • Nausea: occasional stomach upset.
  • Diarrhoea: loose stools.
  • Abdominal pain: mild discomfort in the abdomen.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: including angioedema or anaphylaxis.
  • Joint pain: unexplained arthralgia.
  • Hepatic injury: abnormal liver function tests.
  • Bullous pemphigoid: rare skin blistering disorder.
  • Hypoglycaemia: especially when combined with insulin or sulfonylureas.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Renal function: assess creatinine clearance and adjust dose if necessary.
  • Hepatic impairment: use with caution in patients with moderate liver disease.
  • Concomitant sulfonylureas or insulin: monitor for hypoglycaemia and adjust therapy.
  • Pregnancy: safety not established; avoid unless benefit outweighs risk.
  • Elderly patients: start at lower dose and monitor for adverse events.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Avoid Interactions

Sitagliptin may interact with several medicines. Review the following groups:

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of hypoglycaemia – avoid dose escalation without monitoring.
  • Rifampin: strong enzyme inducer that may reduce sitagliptin exposure – avoid concurrent use.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: monitor renal function and potassium levels.
  • Diuretics: watch for electrolyte disturbances.
  • Warfarin: may increase INR – check coagulation parameters regularly.
  • Digoxin: potential increase in serum digoxin concentration – monitor levels.

Frequently Asked Questions

Jidinum contains sitagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It helps lower blood glucose levels when used together with diet, exercise and, when appropriate, other antidiabetic agents.

Sitagliptin blocks the dipeptidyl‑peptidase‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to improved glycaemic control.

The dose of Jidinum is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function and concomitant therapies. The prescriber determines the appropriate strength and dosing schedule.

Safety of sitagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To order Jidinum, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin offers glucose‑dependent insulin release, which carries a lower intrinsic risk of hypoglycaemia. Relative to other DPP‑4 inhibitors such as saxagliptin or linagliptin, efficacy and safety profiles are broadly similar, with choice often guided by patient tolerance, renal function and formulary considerations.

Jidinum tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Do not store in a refrigerator or freezer.

Jidinum is taken orally as a tablet, usually once daily. It may be taken with or without food, according to the prescribing physician’s instructions.

The most serious adverse events to monitor are pancreatitis, severe allergic reactions such as angioedema or anaphylaxis, and hypoglycaemia when sitagliptin is combined with insulin or sulfonylureas. Prompt medical evaluation is required if any of these occur.

Jidinum should be avoided in patients with a known hypersensitivity to sitagliptin or any component of the formulation, and in those with severe renal impairment unless dose adjustments are made. Caution is also advised for individuals with a history of pancreatitis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT